Sam Brusco, Associate Editor08.07.23
Abbott has gained U.S. Food and Drug Administration (FDA) clearance for its Alinity h-series hematology system, enabling U.S. labs to run complete blood counts (CBCs) as a part of its Alinity family of diagnostic tests.
According to Abbott, CBCs are one of the most ordered tests in the healthcare system. They’re common in routine checkups to screen for infections, anemia, immune diseases, and blood cancers.
The series includes the Alinity hq automated hematology analyzer and Alinity hs integrated slide maker and stainer. Alinity hq uses Abbott’s MAPSS, which leverages light scattering to distinguish cellular features and better identify various blood cells.
Abbott said Alinity h-series is simple to add to existing core lab operations and is easily adopted with minimal training—especially important in labs with strained resources and staff.
“U.S. healthcare systems have experienced significant resource constraints and rapidly shifting dynamics post-pandemic,” Louis Morrone, executive VP for Abbott’s core diagnostics business, told the press. “The Alinity h-series system, as with the entire suite of Alinity products, was developed to transform the way laboratories run tests so they can focus on their most important mission: the delivery of patient care.”
According to Abbott, CBCs are one of the most ordered tests in the healthcare system. They’re common in routine checkups to screen for infections, anemia, immune diseases, and blood cancers.
The series includes the Alinity hq automated hematology analyzer and Alinity hs integrated slide maker and stainer. Alinity hq uses Abbott’s MAPSS, which leverages light scattering to distinguish cellular features and better identify various blood cells.
Abbott said Alinity h-series is simple to add to existing core lab operations and is easily adopted with minimal training—especially important in labs with strained resources and staff.
“U.S. healthcare systems have experienced significant resource constraints and rapidly shifting dynamics post-pandemic,” Louis Morrone, executive VP for Abbott’s core diagnostics business, told the press. “The Alinity h-series system, as with the entire suite of Alinity products, was developed to transform the way laboratories run tests so they can focus on their most important mission: the delivery of patient care.”
Fast facts about the new Alinity h-series system:
- Processes up to 119 CBC results per hour
- Requires less floor space, critical for labs to maximize resources and operations
- Loads samples from the front and from a laboratory automation system
- Ensures urgent samples receive priority without compromising capacity or workflow
- Offers hands-off maintenance so labs can schedule automated daily and weekly cleanings
- Integrates the slide maker with the analyzer to reduce manual intervention
- Provides customizable reports and rules for systems
- Centralizes results and control functions at a single point